Rising Rare Disease Awareness And Precision Medicine Will Expand Access
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
29 May 25
Updated
20 Aug 25
AnalystHighTarget's Fair Value
US$72.75
94.5% undervalued intrinsic discount20 Aug
US$3.97
1Y
-81.9%7D
59.4%1Y
-81.9%7D
59.4%